Single center evaluation of a composite risk assessment model to predict non-relapse mortality following allogeneic hematopoietic cell transplantation (HCT)
Trending
- Actor Tyler Mane reveals he is having treatment for rare male breast cancer | US news
- Investigators Halt Phase 3 Trial of Sacituzumab Govitecan Combo in NSCLC
- Differentiating malignancy from liver parenchyma in Ex-Vivo OCT images using anomaly detection
- Rethinking Academic Support: Sustainability For Clinical Cancer Research
- UK’s stem cell transplant system may be putting lives at risk, report by MPs finds | Stem cells
- CDO1 is a new biomarker to discriminate aggressive forms of prostate cancer
- 'Everyone with blood cancer deserves a donor'
- Integrated multi-omics profiling of treatment-naive cervix uteri premalignant lesions and cervical squamous cell carcinoma reveals ecosystem and drivers underlying cervical cancer progression
Wednesday, June 10
Single center evaluation of a composite risk assessment model to predict non-relapse mortality following allogeneic hematopoietic cell transplantation (HCT)
By NewsCancer
